Literature DB >> 2493323

Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients.

R D Hesch1, U Busch, M Prokop, G Delling, E F Rittinghaus.   

Abstract

Combination therapy with the biologically active (1-38) human parathyroid hormone peptide and calcitonin using pulsatile and sequential activation of the skeleton for 14 months in patients with low-turnover osteoporosis resulted in an increase in trabecular bone mass. These favorable responses were observed without any significant changes in cortical (forearm) bone mass content.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2493323     DOI： 10.1007/bf02556561

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


  26 in total

1.  Type II PTH receptor-operated calcium channel and its importance for PTH peptide elevations in coronary artery disease.

Authors:  R D Hesch; G Herrmann; A D Perris; M J Atkinson
Journal:  Am J Nephrol       Date:  1986       Impact factor: 3.754

2.  Pulsatile secretion of parathyroid hormone and its action on a type I and type II PTH receptor: a hypothesis for understanding osteoporosis.

Authors:  R D Hesch; G Brabant; E F Rittinghaus; M J Atkinson; H Harms
Journal:  Calcif Tissue Int       Date:  1988-06       Impact factor: 4.333

3.  Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

Authors:  G F Mazzuoli; M Passeri; C Gennari; S Minisola; R Antonelli; C Valtorta; E Palummeri; G F Cervellin; S Gonnelli; G Francini
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

Review 4.  Treatment of osteoporoses by manipulation of coherent bone cell populations.

Authors:  H M Frost
Journal:  Clin Orthop Relat Res       Date:  1979-09       Impact factor: 4.176

5.  Chronic response of dogs to parathyroid hormone infusion.

Authors:  J A Parsons; B Reit
Journal:  Nature       Date:  1974-07-19       Impact factor: 49.962

Review 6.  The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part III of IV parts; PTH and osteoblasts, the relationship between bone turnover and bone loss, and the state of the bones in primary hyperparathyroidism.

Authors:  A M Parfitt
Journal:  Metabolism       Date:  1976-09       Impact factor: 8.694

7.  Effects of parathyroid hormone on remodeling of iliac trabecular bone packets in patients with primary hyperparathyroidism.

Authors:  S A Charhon; C M Edouard; M E Arlot; P J Meunier
Journal:  Clin Orthop Relat Res       Date:  1982 Jan-Feb       Impact factor: 4.176

8.  Thyrocalcitonin: inhibitor of bone resorption in tissue culture.

Authors:  J Friedman; L G Raisz
Journal:  Science       Date:  1965-12-10       Impact factor: 47.728

9.  Paracrine interactions in bone-secreted products of osteoblasts permit osteoclasts to respond to parathyroid hormone.

Authors:  G L Wong
Journal:  J Biol Chem       Date:  1984-04-10       Impact factor: 5.157

10.  A two-receptor model for the action of parathyroid hormone on osteoblasts: a role for intracellular free calcium and cAMP.

Authors:  C W Löwik; J P van Leeuwen; J M van der Meer; J K van Zeeland; B A Scheven; M P Herrmann-Erlee
Journal:  Cell Calcium       Date:  1985-08       Impact factor: 6.817
View more
  14 in total

Review 1.  Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

Authors:  J Y Reginster; A N Taquet; G Fraikin; C Gosset; B Zegels
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.

Authors:  J Reeve; U M Davies; R Hesp; E McNally; D Katz
Journal:  BMJ       Date:  1990-08-11

3.  Trabecular bone structure in patients with primary hyperparathyroidism.

Authors:  M Vogel; M Hahn; G Delling
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 4.  The bone-building action of the parathyroid hormone: implications for the treatment of osteoporosis.

Authors:  J F Whitfield; P Morley; G E Willick
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

5.  Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats.

Authors:  V Shen; R Birchman; R Xu; M Otter; D Wu; R Lindsay; D W Dempster
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.

Authors:  H Rico; M Revilla; E R Hernández; L F Villa; M Alvarez de Buergo
Journal:  Calcif Tissue Int       Date:  1995-03       Impact factor: 4.333

Review 7.  Future horizons for calcitonin: a U.S. perspective.

Authors:  J H Carstens; J D Feinblatt
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

8.  Human parathyroid peptide treatment of vertebral osteoporosis.

Authors:  J Reeve; M E Arlot; J N Bradbeer; R Hesp; E Mcally; P J Meunier; J M Zanelli
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 9.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

10.  An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.

Authors:  A B Hodsman; L J Fraher; T Ostbye; J D Adachi; B M Steer
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.